Gilder Gagnon Howe & Co’s Aldeyra Therapeutics ALDX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-218,042	Closed	-$1.31M	–	285
2019 Q2	$1.31M	Sell	218,042 -594	-0.3%	-$4.47K	0.01%	223
2019 Q1	$1.97M	Buy	218,636 +1,489	+0.7%	+$12.7K	0.02%	197
2018 Q4	$1.8M	Sell	217,147 -934	-0.4%	-$9.57K	0.03%	194
2018 Q3	$3.01M	Buy	+218,081	New	+$1.77M	0.03%	194

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Gilder Gagnon Howe & Co's ALDX Position: Q3 2019 in Review

Gilder Gagnon Howe & Co sold out of Aldeyra Therapeutics (ALDX) in Q3 2019, closing a stake of 218,042 shares — an estimated $1.31M sold.

Gilder Gagnon Howe & Co first reported a position in ALDX in Q3 2018 and held it in 4 quarters. The position peaked at $3.01M in Q3 2018. 72 funds tracked by Wall St. Rank hold ALDX as of Q3 2019.

Gilder Gagnon Howe & Co reported no remaining Aldeyra Therapeutics position as of Q3 2019 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 218,042 Aldeyra Therapeutics shares in Q3 2019, an estimated $1.31M.
Gilder Gagnon Howe & Co first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 4 quarters.
Gilder Gagnon Howe & Co's Aldeyra Therapeutics position peaked at $3.01M in Q3 2018.
72 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2019.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2019, filed 14 Nov 2019.